Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Receptor Activation by Human C5a des Arg74 but Not Intact C5a Is Dependent on an Interaction between Glu199 of the Receptor and Lys68 of the Ligand

View Author Information
Department of Medical Microbiology, Medizinische Hochschule, Hannover, Germany, Krebs Institute for Biomolecular Research, Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield, U.K., and Department of Applied Pharmacology, Imperial College School of Medicine at the National Heart & Lung Institute, London, U.K.
Cite this: Biochemistry 1999, 38, 30, 9712–9717
Publication Date (Web):July 2, 1999
Copyright © 1999 American Chemical Society

    Article Views





    Other access options


    Despite the expression of only one type of receptor, there is great variation in the ability of different cell types to discriminate between C5a and its more stable metabolite, C5a des Arg74. The mechanism that underlies this phenomenon is not understood but presumably involves differences in the interaction with the C5a receptor. In this paper, we have analyzed the effects of a substitution mutation of the receptor (Glu199 → Lys199) and the corresponding reciprocal mutants (Lys68 → Glu68) of C5a, C5a des Arg74 and peptide analogues of the C-terminus of C5a on the ability of the C5a receptor to discriminate between ligands with and without Arg74. The use of these mutants indicates that the Lys68/Glu199 interaction is essential for activation of receptor by C5a des Arg74 but not for activation by intact C5a. The substitution of Asp for Arg74 of C5a [Lys68] produces a ligand with equal potency on both the wild-type and mutant receptors, suggesting that it is the C-terminal carboxyl group rather than the side chain of Arg74 that controls the responsiveness of the receptor to Lys68. In contrast, the mutation of Lys68 to Glu68 has little effect on the ability of either C5a or C5a des Arg74 to displace [125I]C5a from the receptors, indicating that binding of ligand and receptor activation are distinct but interdependent events. C5a and the truncated ligand, C5a des Arg74, appear to have different modes of interaction with the receptor and the ability of the human C5a receptor to discriminate between these ligands is at least partly dependent on an interaction with the receptor residue, Glu199.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

     This work is supported by a fellowship grant from the Arthritis and Rheumatism Campaign M0543 (to P.N.M.), the British Heart foundation project Grant PG95119 (to P.N.M.) and a grant from the Niedersachsische Vorab der Volkswagenstiftung (to W.B.).

     Department of Medical Microbiology.


     Krebs Institute for Biomolecular Research.

     Department of Applied Pharmacology.


     To whom correspondence should be addressed:  Department of Molecular Biology and Biotechnology, University of Sheffield, Firth Court, Sheffield, S10 2UH. Phone:  +44 114 2224188. Fax:  +44 114 2728697. E-mail:  [email protected]

    Cited By

    This article is cited by 16 publications.

    1. Gregory V. Nikiforovich, Garland R. Marshall and Thomas J. Baranski . Modeling Molecular Mechanisms of Binding of the Anaphylatoxin C5a to the C5a Receptor. Biochemistry 2008, 47 (10) , 3117-3130.
    2. Ling-Ling An, Jacob V. Gorman, Geoffrey Stephens, Bonnie Swerdlow, Paul Warrener, Jessica Bonnell, Tomas Mustelin, Michael Fung, Roland Kolbeck. Complement C5a induces PD-L1 expression and acts in synergy with LPS through Erk1/2 and JNK signaling pathways. Scientific Reports 2016, 6 (1)
    3. Soumendra Rana, Amita Rani Sahoo. Model structures of inactive and peptide agonist bound C5aR: Insights into agonist binding, selectivity and activation. Biochemistry and Biophysics Reports 2015, 1 , 85-96.
    4. Andreas Klos, Elisabeth Wende, Kathryn J. Wareham, Peter N. Monk. International Union of Basic and Clinical Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors. Pharmacological Reviews 2013, 65 (1) , 500-543.
    5. Edimara S. Reis, Hui Chen, Georgia Sfyroera, Peter N. Monk, Jörg Köhl, Daniel Ricklin, John D. Lambris. C5a Receptor-Dependent Cell Activation by Physiological Concentrations of Desarginated C5a: Insights from a Novel Label-Free Cellular Assay. The Journal of Immunology 2012, 189 (10) , 4797-4805.
    6. Reena Halai, Daniel E. Croker, Jacky Y. Suen, David P. Fairlie, Matthew A. Cooper. A Comparative Study of Impedance versus Optical Label-Free Systems Relative to Labelled Assays in a Predominantly Gi Coupled GPCR (C5aR) Signalling. Biosensors 2012, 2 (3) , 273-290.
    7. Shuang Liang, Jennifer L. Krauss, Hisanori Domon, Megan L. McIntosh, Kavita B. Hosur, Hongchang Qu, Fenge Li, Apostolia Tzekou, John D. Lambris, George Hajishengallis. The C5a Receptor Impairs IL-12–Dependent Clearance of Porphyromonas gingivalis and Is Required for Induction of Periodontal Bone Loss. The Journal of Immunology 2011, 186 (2) , 869-877.
    8. P N Monk, A‐M Scola, P Madala, D P Fairlie. Function, structure and therapeutic potential of complement C5a receptors. British Journal of Pharmacology 2007, 152 (4) , 429-448.
    9. Andrew J. Wright, Adrian Higginbottom, Didier Philippe, Abhishek Upadhyay, Stefan Bagby, Robert C. Read, Peter N. Monk, Lynda J. Partridge. Characterisation of receptor binding by the chemotaxis inhibitory protein of Staphylococcus aureus and the effects of the host immune response. Molecular Immunology 2007, 44 (10) , 2507-2517.
    10. Adrian Higginbottom, Stuart A. Cain, Trent M. Woodruff, Lavinia M. Proctor, Praveen K. Madala, Joel D.A. Tyndall, Stephen M. Taylor, David P. Fairlie, Peter N. Monk. Comparative Agonist/Antagonist Responses in Mutant Human C5a Receptors Define the Ligand Binding Site. Journal of Biological Chemistry 2005, 280 (18) , 17831-17840.
    11. Magnus Otto, Heiko Hawlisch, Peter N. Monk, Melanie Müller, Andreas Klos, Christopher L. Karp, Jörg Köhl. C5a Mutants Are Potent Antagonists of the C5a Receptor (CD88) and of C5L2. Journal of Biological Chemistry 2004, 279 (1) , 142-151.
    12. Stuart A. Cain, Adrian Higginbottom, Peter N. Monk. Characterisation of C5a receptor agonists from phage display libraries. Biochemical Pharmacology 2003, 66 (9) , 1833-1840.
    13. Stuart A. Cain, Peter N. Monk. The Orphan Receptor C5L2 Has High Affinity Binding Sites for Complement Fragments C5a and C5a des-Arg74. Journal of Biological Chemistry 2002, 277 (9) , 7165-7169.
    14. Stuart A. Cain, Trent M. Woodruff, Stephen M. Taylor, David P. Fairlie, Sam D. Sanderson, Peter N. Monk. Modulation of ligand selectivity by mutation of the first extracellular loop of the human C5a receptor 1 1Abbreviations: C5aR, human complement fragment 5a receptor; WT, wild-type; G105D, C5aR mutated to aspartate at glycine105; P103Y, C5aR mutated to tyrosine at proline105; P103Y/G105D, C5aR containing both substitutions; C5adR74, des arginated C5a; F-[OPchaWR], phenylalanine [l-ornithine-proline-d-cyclohexylalanine-tryptophan-arginine]; MeFKPchaWr, N-methyl-l-phenylalanine-lysine-proline-d-cyclohexylalanine-tryptophan-d-arginine; PMN, polymorphonuclear leukocytes; PCR, polymerase chain reaction; YSFKPMPLaR, l-tyrosine-serine-phenylalanine-lysine-proline-methionine-proline-leucine-d-alanine-arginine; and YSFKD(MeNle)PIAR, l-tyrosine-serine-phenylalanine-lysine-aspartate-N-methylnorleucine-proline-d-leucine-alanine-arginine.. Biochemical Pharmacology 2001, 61 (12) , 1571-1579.
    15. S.A. Cain, D.M. Williams, V. Harris, P.N. Monk. Selection of novel ligands from a whole-molecule randomly mutated C5a library. Protein Engineering, Design and Selection 2001, 14 (3) , 189-193.
    16. Santa Eglite, Katharina Plüss, Clemens A. Dahinden. Requirements for C5a Receptor-Mediated IL-4 and IL-13 Production and Leukotriene C4 Generation in Human Basophils. The Journal of Immunology 2000, 165 (4) , 2183-2189.